Veeda Clinical Research: CX Partners-led consortium looks to sell majority stake, eyes $600 mn -$650 mn valuation
28 Apr 2024
• Moneycontrol
Veeda Clinical Research Share Price
DMAT
PUBLIC LIMITED
Price Chart
High
₹467
Low
₹466
Return
-0.21%
Buy Sell Veeda Clinical Research Unlisted Shares
As of November 07, 2026, Veeda Clinical Research, Unlisted Shares are trading at ₹467.00 per share and face value is ₹2.00/share, with a 52-week high of ₹467.00 and 52-week low of ₹467.00. The minimun lot size is 500 shares, and the shares are traded on .
ISIN
INE01HQ01026
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
2
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Shares
6,57,77,495
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Market Cap
3,071.81 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Profit After Tax
0 None
It is the final profit left over after subtracting all operating and non operating items from net revenue.
Total Revenue
0 None
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Pharmaceuticals
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Pre IPO
Category is defined as a class or division of things regarded as having particular shared characteristics.
About Veeda Clinical Research
- Overview: Veeda Clinical Research, a leading CRO in India, has been operating for two decades, providing comprehensive services across various stages of drug development including preclinical, early phase, and late-phase clinical trials, bioanalytical assessment, and drug launch.
- Technical Expertise: The organization specializes in pharmacokinetics (PK) studies and trials for generic molecules, new chemical entities, large molecules, and biosimilars, with an impressive ISR (Incurred Sample Reanalysis) rate of >95%, surpassing the USFDA recommended rate of 67%.
- Service Spectrum: Veeda offers bioavailability (BA) & bioequivalence (BE) studies, bioanalytical research, medical writing, pharmacovigilance, preclinical trials, clinical trials (Phase I to Phase III), biosimilars, biopharmaceutics, data science, and post-marketing surveillance.
- Bioanalytical Research: Developed over 1,000 bioanalytical methods, including 860 generics, 70+ complex generics, 30+ large molecule assays, and 70+ in-house methods.
- Clinical Trial Expertise: Provides a range of clinical development programs to pharmaceutical, biotech, generic, and medical device companies, ensuring fully ICH-GCP compliant operations, including early phase (Phase I) and late phase (Phase II & III) clinical trials.
- Biosimilars: Through a joint venture with Ingenuity Biosciences, Veeda offers specialized clinical services including PK antidrug antibodies, neutralizing antibodies, and biomarker assays, as well as characterization and comparability testing.
- Global Reach: With a significant client base in North America, Europe, and Asia, Veeda generates approximately 70% of its revenue from overseas clients.
- Facilities: Operates around 7 facilities, each catering to different stages of the drug development cycle, and has a subsidiary, Bioneeds, for preclinical research, providing an operational edge.
- Clients: Veeda Clinical Research has completed studies for numerous high-profile clients worldwide, including Dr. Reddy’s Laboratories Limited, Mankind Pharma Limited, and Granules India Limited in India; Laboratorios Liconsa, S.A (Chemo) in Europe; Novugen Pharma (Malaysia) SDN. BHD. in Malaysia; Sunshine Lake Pharma Co. Ltd and Ǫilu Pharmaceutical Co., Ltd in China; and Upsher-Smith Laboratories LLC and Osmotica Pharmaceutical US LLC in the USA.
Want to See a Detailed Investment Analysis?
Explore in-depth financial analysis, performance metrics, and key disclosures.
Veeda Clinical Research Media
News
Articles
Videos
Veeda Clinical Research buys European CRO Heads for an undisclosed sum
25 Mar 2024
• Business Standard
CX Partners Backed Veeda Gets SEBI Nod For IPO
27 Dec 2021
• VC Circle
Frequently Asked Question (FAQs)
The Veeda Clinical Research Share Price is Rs 529
The CEO of Veeda Clinical Research is Dr. Mahesh Bhalgat.